Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A network-based framework to discover treatment-response-predicting biomarkers for complex diseases

ABSTRACT: A network-based framework to discover treatment-response-predicting biomarkers for complex diseases

PROVIDER: PRJNA1085755 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

A network-based framework to discover treatment-response-predicting biomarkers for complex diseases

Project description:Precision medicine's potential to transform complex autoimmune-disease treatment is often challenged by limited data availability and inadequate sample size when compared to the number of molecular features found in high-throughput multi-omics datasets. Addressing this issue, the novel framework PRoBeNet (Predictive Response Biomarkers using Network medicine) was developed. ProBeNet operates under the hypothesis that the therapeutic effect of a drug propagates through a protein–protein interaction network to reverse disease states. ProBeNet prioritizes biomarkers by considering (1) therapy-targeted proteins, (2) disease-specific molecular signatures, and (3) an underlying network of interactions among cellular components (the human interactome). With ProBeNet, biomarkers were discovered predicting patient responses to both an established autoimmune therapy (infliximab) and an investigational compound (a MAPK3/1 inhibitor). Predictive power of ProBeNet biomarkers was validated with retrospective gene-expression data from ulcerative-colitis and rheumatoid-arthritis patients and prospective data from ulcerative-colitis and Crohn’s disease patient-derived tissues. Machine-learning models using ProBeNet biomarkers significantly outperformed models using either all genes or randomly selected genes, especially when data were limited (fewer than 20 samples). These results illustrate the value of ProBeNet for reducing features and for constructing robust machine-learning models when limited data are available. ProBeNet may be used to develop companion and complementary diagnostic assays for complex autoimmune-disease therapies, which may help stratify suitable patient subgroups in clinical trials, approve new drugs, and improve patient outcomes.

2024-03-13 | GSE261205 | GEO

Biomarkers for Detecting and Predicting Infections in Transplant Recipients

Project description:Biomarkers for Detecting and Predicting Infections in Transplant Recipients

| PRJNA1290679 | ENA

Biomarkers for Detecting and Predicting Infections in Transplant Recipients

Project description:Biomarkers for Detecting and Predicting Infections in Transplant Recipients

| PRJNA1290677 | ENA

Biomarkers for Predicting Therapeutic Response to Preoperative Chemoradiotherapy in Rectal Cancer

Project description:Biomarkers for Predicting Therapeutic Response to Preoperative Chemoradiotherapy in Rectal Cancer

| PRJNA1297161 | ENA

RegSNPs-intron: a computational framework for predicting pathogenic impact of intronic single nucleotide variants

Project description:RegSNPs-intron: a computational framework for predicting pathogenic impact of intronic single nucleotide variants

| PRJNA574846 | ENA

A novel translational in-silico indication discovery framework identifies indications and predictive biomarkers for cenerimod

Project description:To fully explore a drug candidate's therapeutic potential, assessing its effectiveness across all possible diseases is essential. While traditional approaches match drug mechanisms to disease pathophysiology, they are limited by the high costs and slow progress of preclinical and clinical trials. This study introduces a novel in silico framework to identify new indications for drug candidates or repurpose approved drugs by analyzing their effects on gene expression in patients or animal models compared to controls. The framework integrate data from 13,602 patient samples across 146 diseases with drug candidate tested in preclinical models and use a neural network to reduce noise and improve sensitivity. The framework was exemplified with cenerimod, a S1P1 receptor modulator, which predicted its efficacy in immune-related diseases such as SLE, Psoriasis, and Crohn’s disease and kidney transplantation complications. Additionally, it identified six genes predictive of maximal clinical response in SLE patients, validated using RNA-seq data from a phase 2b cenerimod trial.

2025-05-31 | GSE293404 | GEO

A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia

Project description:A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia

| PRJNA820009 | ENA

Biomarkers in Predicting Neurotoxicity in Patients With Colorectal Cancer Receiving Oxaliplatin

Project description:RATIONALE: Studying samples of blood in the laboratory from patients receiving oxaliplatin for cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to neurotoxicity. PURPOSE: This phase II trial is studying biomarkers in predicting neurotoxicity in patients with colorectal cancer receiving oxaliplatin.

| 2071054 | ecrin-mdr-crc

Identification of tumor-agnostic biomarkers for predicting prostate cancer progression and biochemical recurrence

Project description:Identification of tumor-agnostic biomarkers for predicting prostate cancer progression and biochemical recurrence

| PRJNA1023930 | ENA

Predicting the Prevalence of Complex Genetic Diseases from Individual Genotype Profiles Using Capsule Networks

Project description:Predicting the Prevalence of Complex Genetic Diseases from Individual Genotype Profiles Using Capsule Networks

| PRJNA909909 | ENA